Last reviewed · How we verify

Asclera (POLIDOCANOL)

Provensis · FDA-approved approved Small molecule Quality 50/100

Asclera works by causing inflammation and scarring in targeted veins, leading to their closure.

Asclera (polidocanol) is a sclerosing agent used to treat venous varices. It is a small molecule modality originally developed by Chemisch FBRK Krsslr and currently owned by Provensis. Asclera works by causing inflammation and scarring in the targeted veins, leading to their closure. It was FDA-approved in 2010 and remains a branded product. Key safety considerations include potential allergic reactions and nerve damage.

At a glance

Generic namePOLIDOCANOL
Also known aslauromacrogol 400, lauromacrogol
SponsorProvensis
Drug classSclerosing Agent [EPC]
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved
First approval2010

Mechanism of action

The active ingredient of Asclera is polidocanol.Polidocanol is sclerosing agent that locally damages the endothelium of blood vessels. When injected intravenously, polidocanol induces endothelial damage. Platelets then aggregate at the site of damage and attach to the venous wall. Eventually, dense network of platelets, cellular debris, and fibrin occludes the vessel. Finally, the occluded vein is replaced with connective fibrous tissue.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: